 CRANBURY, N.J., May 14, 2021 GLOBE NEWSWIRE -- PMV Pharmaceuticals, Inc. Nasdaq: PMVP, a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the quarter ended March 31, 2021 and provided corporate highlights. 